Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Illustration: Sarah Grillo/Axios
President Trump's health care agenda is making more enemies than friends, hitting brick walls and fierce opposition in the courts, in Congress and even within his own administration.
Driving the news: Yesterday was a bad day for two of Trump's biggest health care priorities.
- A federal judge slapped down the administration's approval of Medicaid work requirements — arguably the biggest change it has actually made to health policy so far.
- Some congressional Republicans, meanwhile, are quietly (and not-so-quietly) hoping the administration will also lose the separate lawsuit in which it's trying to get the Affordable Care Act thrown out.
The big picture: These are different kinds of setbacks, and there's still a long way to go in all of these legal proceedings. But together, the crosswinds — the political resistance on one side and substantive losses on the other — leave Trump's agenda in a precarious place.
This will keep happening. The administration appears close to finalizing the part of its drug-pricing plan that calls for including drugs' sticker prices in their TV ads. The pharmaceutical industry will likely challenge that proposal in court.
- Another component on drug prices — the plan to tie Medicare payments for certain drugs to the prices European countries pay — is still a hard sell for some conservatives on Capitol Hill.
- They are giving the administration the benefit of the doubt now, but — as we're beginning to see with the ACA lawsuit — the benefit of the doubt doesn't always last forever.
Go deeper: Kevin McCarthy tells Trump new health care push makes no sense